What question did this study set out to answer?

To evaluate the long-term, 7-year efficacy and survival outcomes of adjuvant paclitaxel and trastuzumab in patients with small, node-negative HER2-positive breast cancer.

May 20, 2017Journal of Clinical Oncology

Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC).

View Full Paper

Ask AI

Bookmark

To evaluate the long-term, 7-year efficacy and survival outcomes of adjuvant paclitaxel and trastuzumab in patients with small, node-negative HER2-positive breast cancer.
Multicenter single-arm phase II trial (NCT00542451) enrolling 410 patients (406 treated) with HER2-positive, node-negative (or ≤1 micrometastasis) breast cancer and tumors <3 cm.
Patients received weekly paclitaxel (80 mg/m²) with weekly trastuzumab for 12 weeks, followed by trastuzumab monotherapy for 39 weeks; median follow-up was 6.5 years.
The 7-year disease-free survival (DFS) was 93.3% (95% CI, 90.4–96.2%), with a 7-year DFS of 94.6% (95% CI, 91.8–97.5%) in hormone receptor-positive patients and 90.7% (95% CI, 84.6–97.2%) in hormone receptor-negative patients.
A total of 23 DFS events were reported, including 4 distant recurrences (1.0%), 5 locoregional recurrences (1.2%), 6 contralateral breast cancers (1.5%), and 8 deaths without recurrence (2.0%).
Secondary endpoints demonstrated a 7-year recurrence-free interval of 97.5% (95% CI, 95.9–99.1%), breast cancer-specific survival of 98.6% (95% CI, 97.0–100%), and overall survival of 95.0% (95% CI, 92.4–97.7%).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Phase 2 trial demonstrates a 93.3% 7-year disease-free survival with adjuvant paclitaxel and trastuzumab in small HER2-positive breast cancer, supporting this regimen as a standard treatment.

Cite This Study

Tolaney et al. (2017) studied this question.

synapsesocial.com/papers/6a1bd69d1567d2fc4d5f1cfe https://doi.org/10.1200/jco.2017.35.15_suppl.511

View Full Paper

Ask AI

Bookmark

Implication

Phase 2 trial demonstrates a 93.3% 7-year disease-free survival with adjuvant paclitaxel and trastuzumab in small HER2-positive breast cancer, supporting this regimen as a standard treatment.

Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC).

Key Points

Discussion

Implication

Cite This Study

Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC).

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider